New Pancreatic Cancer Study Results from Gifu Municipal Hospital Described (A Phase-i Study of Second-line S-irox for Unresectable Pancreatic Cancer After Gemcitabine Plus Nab-paclitaxel Failure).

A new study conducted at Gifu Municipal Hospital in Japan explores the use of S-IROX as a second-line treatment for unresectable pancreatic cancer after the failure of first-line therapy with Gemcitabine plus nab-paclitaxel. The study used a dose-escalation design and found that the recommended dose of S-IROX was S-1 at 80 mg/m2, oxaliplatin at 85 mg/m2, and irinotecan at 150 mg/m2. The study showed promising results, with a response rate of 33.3% and a disease control rate of 77.8%. Further research is needed to validate these findings. [Extracted from the article]